Seroatlas · Human Serome Atlas

VPS9D1

VPS9 domain-containing protein 1

Also known as: ATP-BL, C16orf7, VP9D1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9Y2B5
Gene: VPS9D1
Ensembl: ENSG00000075399
Chromosome: 16
Canonical length: 631 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Cytosol

OverviewNCBI Gene

Enables identical protein binding activity. Predicted to be involved in proton motive force-driven ATP synthesis. Predicted to be active in cytosol and endocytic vesicle. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

631 residues, UniProt reviewed canonical sequence.

>Q9Y2B5|VPS9D1
     1  MAAAAGDGTV KPLQSAMKLA NGAIELDTGN RPREAYTEYL RSIHYISQVL LEEVETTKEA
    61  GETVPPDTSK MLKLAQQCLE RAQSTAAKLG KTRLKPTMPA AAPIPQPAGR HRRVYSDEGG
   121  KLSPFLPPEI FQKLQGAESQ SCKKELTPLE EASLQNQKLK AAYEARMARL DPSQAMQKTS
   181  LTLSLQRQMM ENLVIAKARE ETLQRKMEER RLRLQEAANR RFCSQVALTP EEREQRALYA
   241  AILEYEQDHD WPKHWKAKLK RNPGDLSLVT SLVSHLLSLP DHPIAQLLRR LQCSVYSALY
   301  PAVSRAAAPA PGCCPPTPNP GSRRLRPSQS LHCMLSPPEP SAAPRPQDSP PTPPLQPGPV
   361  GSPSPLGDTA SGLPDKDSSF EDLEQFLGTS ERQGRGRGVQ PEPQLQQLKT AVEEIHNAVD
   421  RLLSLTLLAF EGLNTAASKD RCLACIEEPF FSPLWPLLLA LYRSVHRARE AALSRSMELY
   481  RNAPPTAIGI PTKLLPQNPE AKGATGYPYC AAAQELGLLV LESCPQKKLE CIVRTLRIIC
   541  VCAEDYCPTP EATPQAGPPP IAAAAIGADD LLPILSFVVL RSGLPQLVSE CAALEEFIHE
   601  GYLIGEEGYC LTSLQSALSY VELLPRGGLA K

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VPS9D1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.4
Highest tissue expression: 44 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 44 nTPM
cerebellum: 39 nTPM
esophagus: 33 nTPM
pituitary gland: 31 nTPM
liver: 31 nTPM
spleen: 29 nTPM

Single-cell type

neutrophils: 193 nCPM
retinal ganglion cells: 100 nCPM
gonadotrophs: 60 nCPM
esophageal apical cells: 59 nCPM
other brain neurons: 59 nCPM
esophageal suprabasal cells: 57 nCPM

Immune cell

neutrophil: 18 nTPM
basophil: 2.2 nTPM
classical monocyte: 0.6 nTPM
intermediate monocyte: 0.5 nTPM
naive B-cell: 0.4 nTPM
naive CD4 T-cell: 0.4 nTPM

Brain region

cerebral cortex: 69 nTPM
pons: 51 nTPM
medulla oblongata: 50 nTPM
amygdala: 47 nTPM
white matter: 46 nTPM
basal ganglia: 45 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.31
gnomAD pLI: 0
gnomAD missense Z: -0.15
DepMap mean gene effect: -0.12
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of VPS9D1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

IST1

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VPS9D1 as an antibody target. Whether an autoantibody or antibody against VPS9D1 could matter depends on whether native VPS9D1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VPS9D1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label VPS9D1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...